Grant

An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis

Sponsored by Momenta Pharmaceuticals

$51K Funding

1 People

External

Related Topics

drug safety, treatment efficacy, myasthenia gravis, clinical trial, patient tolerability

People

Katalin Scherer
Principal Investigator (PI)
Neurology﹒Professor